Table 3.
Long-term outcomes of surgery for MEN1-ZES.
| Parameter | ALL (n = 35) |
PD (n = 11) |
Thompson (n = 12) |
DUODX (n = 12) |
p-Value PD vs. Non-PD * |
|---|---|---|---|---|---|
| Median Follow-up, months (range) | 134 (6–480) | 134 (49–256) | 148 (6–480) | 69 (14–352) | 0.757 |
| Normal Gastrin | 14/35 (40%) | 9/11 (82%) | 2/12 (16%) | 3/12 (25%) | 0.007 |
| Reoperation for recurrent/persistent ZES | 9/35 (26%) | 1/11 (9%) | 4/12 (33%) | 4/12 (33%) | 0.080 |
| Reoperation for other pNENs | 4/35 (11%) | 1/11 (9%) | 0/12 | 3/12 (25%) | 0.566 |
| Development of distant gastrinoma metastases | 6/35 (17%) | 1/11 (9%) | 3/12 (25%) | 2/12 (17%) | 0.353 |
| Development of distant metastases from other NEN | 6/35 (17%) | 1/11 (9%) | 1/12 (8%) | 4/12 (33%) | 0.353 |
| Insulin-dependent diabetes mellitus | 14/35 (40%) | 3/11 (27%) | 6/12 (50%) | 5/12 (41%) # | 0.301 |
| Pancreastic enzyme medication | 14/35 (40%) | 4/11 (36%) | 6/12 (50%) | 4/12 (33%) # | 0.359 |
| Overall survival, months(range) | 106 (6–480) | 134 (49–256) | 148 (6–480) | 69 (14–352) | 0.757 |
| Disease-free survival, months (range) | 61 (0–480) | 134 (49–256) | 70 (0–480) | 44 (0–138) | 0.001 |
| QoL-score (EORTC QlC30) | 64 | 76.9 | 57.4 | 59.5 | 0.1963 |
| ZES disease status | |||||
| NED | 14/35(40%) | 9/11 (82%) | 2/12 (16%) | 3/12 (25%) | <0.001 |
| AWD | 18/35(51%) | 1/11 (9%) | 9/12 (75%) | 8/12 (67%) | <0.001 |
| DOD | 0/35 | 0/11 | 0/12 | 0/12 | 1 |
| DURC § | 4/35 (11%) | 1/11 (9%) | 1/12 (8%) | 2/12 (16%) | 0.777 |
NED = no evidence of disease; AWD = alive with disease; DOD = dead of disease; DURC = dead of unrelated cause; ZES = Zollinger–Ellison syndrome; pNEN = pancreatic neuroendcocrine neoplasm; * non PD resections include both Thompson procedure and DUODX + LAD; # includes status after reoperations; § includes metastatic thymic carcinoid, metastatic gastric NEC, myocardial infarction, and liver metastasis of a colon carcinoma.